CLINICAL TRIAL PROTOCOL : NE3107 -TRP -001 
Study  Title:  A Phase II Open -Label Study for the Use of Anti -Inflammatory, 
Insulin -Sensitizing NE3107 for Treatment of Cognitive Decline Due to 
Degenerative Dementias  
Study  Number:  NE3107 -TRP-001 
Study Phase:  [ADDRESS_754975] Name:  [INVESTIGATOR_44466]3107 (17a-ethynyl -androst -5-ene-3b,7b,17b -triol)  
IND Number:  159271  
Indication:  Degenerative Dementias  
Investigators:  Principal Investigator: [INVESTIGATOR_124]. Sheldon E. Jordan, M.D., F.A.A.N.  
Sub-Investigator: [CONTACT_575168], M.D.  
 
  
Sponsor:  The Regenesis Project  
Sponsor Contact:  [CONTACT_575134], MD  
Sponsor’s Legal 
Representative:  Stephanie Berg, ND, JD  
[ADDRESS_754976]., #242  
Santa Monica, CA [ZIP_CODE]  
Medical Monitor : Sheldon Jordan, MD  
 
  
Original  Protocol : 11/04/2021  
Amendment 1:  Version 2, dated 12/1 7/[ADDRESS_754977]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 2  
 
 SYNOPSIS  
Sponsor :  Sheldon Jordan MD Inc., dba The Regenesis Projec t 
Name [CONTACT_2756]:   NE3107  
Name [CONTACT_3261]:   17a-ethynyl -androst -5-ene-3b,7b,17b -triol 
Study  Title :  A Phase II Open -Label Study for the Use of Anti-Inflammatory, Insulin -Sensitizing 
NE3107 for Treatment of Cognitive Decline Due to Degenerative Dementias  
Study Number:   NE3107 -TRP-001 
Study Phase:  2  
Primary Objective (s):  
Primary endpoints will involve a comparison of neurophysiological health as evaluated by [CONTACT_7163] -
modal brain MRIs obtained at baseline and post -intervention termination (3 months).  
Secondary Objective (s): 
Secondary endpoints will include a longitudinal comparison of cognitive functioning as well as 
serological inflammatory markers and glucose and insulin homeostasis . 
Study Design : 
The present open label study is designed t o evaluate the potential efficacy of NE3107 among 
patients with degenerative dementias through neuroimaging, cognitive performance te sting, and  
serological measures of insulin resistance . 
Study Population :  
Approximately 25 participants  are planned  to be enrolled in this study . 
Diagnosis and Main Criteria for Inclusion  
Inclusion criterion are a diagnosis of cognitive decline due to degenerative dementia and a clinical 
dementia rating (CDR) score of 0.[ADDRESS_754978];  Dose ; and Mode of Administration:  
NE3107 20mg BID  
Duration of Treatment:  
The duration of active intervention will be three (3) months.  
Pharmacokinetic Variables : 
The terminal plasma t1/2 for NE3107 is 6 -8 hours. The estimated time to reach steady -state drug 
concentrations is 3 days using BID daily dosing.  
Safety  Assessments : 
Safety and tolerability will be assessed using incidence reports, vital sign measurement s, physical 
examinations, and clinical laboratory assessments.  
Statistical Methods:  
Statistical analyses will be run to compare change from baseline at the post -intervention 
termination follow -up (three months after baseline) using a level of significanc e of 0.05.   
Date of Original Protocol : [ADDRESS_754979] Recent Protocol Amendment (if applicable): Version 2, dated 1 7 December 2021  
Prepared in:  Microsoft  Word version [ADDRESS_754980]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754981] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ................................ ............ 7 
1 INTRODUCTION  ................................ ................................ ................................ .11 
2 STUDY OBJECTIVES  ................................ ................................ .......................... 13 
2.1 Primary Objective(s)  ................................ ................................ ........................ 13 
2.2 Secondary Objective(s)  ................................ ................................ .................... 13 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................ 14 
3.1 Overall Study Design and Plan  ................................ ................................ ........ 14 
3.2 Rationale for Study Design and Control Group  ................................ ............... 14 
3.3 Study Duration and Dates  ................................ ................................ ................ 14 
4 STUDY POPULATION SELECTION  ................................ ................................ .15 
4.1 Study Population  ................................ ................................ .............................. 16 
4.2 Inclusion Criteria  ................................ ................................ ............................. 16 
4.3 Exclusion Criteria  ................................ ................................ ............................ 16 
5 STUDY TREATMENT(S)  ................................ ................................ .................... 18 
5.1 Description of Treatment(s)  ................................ ................................ ............. 18 
5.1.1  Study Drug  ................................ ................................ ........................... 18 
5.1.2  Placebo or Control  ................................ ................................ ............... 18 
5.2 Treatment(s) Administered  ................................ ................................ .............. [ADDRESS_754982]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 4  
 
 6.5 Electrocardiography and Continuous Telemetry Monitoring  .......................... 23 
6.5.1  12-Lead Electrocardiograms  ................................ ................................ 23 
6.5.2  Continuous Holter Monitoring  ................................ ............................. 23 
6.6 Clinical Laboratory Tests  ................................ ................................ ................. 23 
6.6.1  Laboratory Parameters  ................................ ................................ ......... 23 
6.6.2  Sample Collection, Storage, and Shippi[INVESTIGATOR_007]  ................................ .......... 26 
6.7 Dispensing Study Drug  ................................ ................................ .................... 26 
6.8 Pharmacokinetic Assessments  ................................ ................................ ......... 27 
6.9 Adverse Events Assessments  ................................ ................................ ........... 27 
6.9.1  Timing  ................................ ................................ ................................ ..28 
6.9.2  Severity  ................................ ................................ ................................ 28 
6.9.3  Relationship  ................................ ................................ ......................... 28 
6.9.4  Expe ctedness  ................................ ................................ ........................ 29 
6.9.5  Clinical Significance  ................................ ................................ ............ 29 
6.9.7  Serious Adverse Events  ................................ ................................ .......29 
 Definition  ................................ ................................ .................... 29 
 Reporting Serious Adverse Events  ................................ ............. 29 
6.10  Concomitant Medication Assessments  ................................ ............................ 29 
6.11  Removal of Participants  from the Trial or Study Drug ................................ ....29 
7 STUDY ACTIVITIES  ................................ ................................ ........................... 31 
7.1 Screening Visit (Days –10 to -1) ................................ ................................ .....31 
7.2 Clinic Admission (Day 0)  ................................ ................................ ................ 32 
7.3 Treatment Period (Day 1 to Day 90)................................ ................................ 32 
7.4 Early Termination Procedures  ................................ ................................ ......... 33 
7.5 Follow -up Visit (Day 91 ± 15)................................ ................................ ......... 33 
8 QUALITY CONTROL AND ASSURANCE  ................................ ....................... 31 
9 PLANNED STATISTICAL METHODS  ................................ .............................. 36 
9.1 General Considerations  ................................ ................................ .................... 36 
9.2 Determination of Sample Size  ................................ ................................ ......... 36 
9.3 Analysis Populations  ................................ ................................ ........................ 36 
9.4 Demographics and Baseline Characteristics  ................................ .................... 37 
9.5 Statistical Analysis of  Endpoints  ................................ ................................ .....37 
      9.5.1         Statistical Analysis of Primary Imaging Endpoints……………..37  
      9.5.2         Statistical Considerations for Secondary Endpoints………...…..[ADDRESS_754983] (IRB) Approval  ................................ .................... [ADDRESS_754984]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754985] of the Study  ................................ ................................ ........... 44 
10.4  Participan t Information and Consent  ................................ ............................... 44 
10.5  Participant  Confidentiality  ................................ ................................ ............... 45 
10.6  Study Monitoring  ................................ ................................ ............................. 46 
10.7  Case Report Forms and Study Records  ................................ ........................... 46 
10.8 Protocol Violations/Deviations  ................................ ................................ ........ [ADDRESS_754986]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754987] OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ..................... 55 
Appendix 4  Sponsor Signatures ................................ ................................ ..................... 56 
Appendix 5  Investigator’s Signature  ................................ ................................ ............. [ADDRESS_754988]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754989] OF  ABBREVIATIONS  
Abbreviation  Definition  
A Amyloid beta  
Abin2  A20 binding inhibitor of NF appaB activation 2  
AChEI  Acetylcholine esterase inhibitor  
AD Alzheimer’s disease  
ADAS -Cog 11  Alzheimer’s Disease assessment Scale -Cognitive Subscale 11  
ADCOMS  Alzheimer’s disease composite score  
ADCS -CGIC  Alzheimer’s Disease Cooperative Study -Clinical Global Impression of 
Change  
ADME  Absorption, distribution, metabolism, and excretion  
AE Adverse event  
API [INVESTIGATOR_575108](1 -4) Apolipoprotein E  
APP amyloid precursor protein  
Arrestin  adaptor/scaffold proteins involved in inhibition of GPCR -mediated & 
intracellular signaling pathways  
AUC  Time integrated drug exposure area under the curve  
BACE1  beta secretase (cleaves APP)  
BBB  Blood -brain barrier  
BDNF  brain -derived neurotrophic factor  
BID twice daily  
BMI  Body mass index  
CCR2  C-C motif chemokine receptor 2 (binds MCP1)  
CDR  Clinical Dementia Rating Scale  
CHO  Chinese hamster ovarary (cell line)  
Cmax Maximum concentration of drug in plasma or serum  
CNS  Central nervous system  
cPLA 2 phospholipase A2  
CRP  C-reactive protein  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CXCL  C-X-C motif chemokine ligand  
CYP  Cytochrome P450  
EAE  experimental autoimmune encephalomyelitis  
EC 50 half maximal effective concentration  
ECG(EKG)  Electrocardiogram  
eGFR  Estimated glomerular filtration rate  
ERK1, ERK2  extracellular signal regulated kinase 1 and 2  
F(%)  Percent absolute oral bioavailability  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 8  
 
 Abbreviation  Definition  
GABA  gamma amino butyric acid  
GD Gestation day  
GDS -SF Geriatric Depression Scale Short Form  
GLP  Good laboratory practice  
GRK  G protein -coupled receptor kinase  
HbA1c  hemoglobin A1c  
HDL  High -density lipoprotein  
HE3129  3,7-dihydroxy -androst -5-en-17-one 
HE3291  17-ethynyl -androst -5-ene-3,7,17-triol 
HE3393  17-ethynyl -3,17-dihydroxy -androst -5-en-7-one 
HE3892  17-ethynyl -androst -5-ene-2,3,7,17-tetrol  
HE3545  17-ethynyl -androst -5-ene-3,7,17-triol 
HE3633  17-ethynyl -17-hydroxy -androst -4,6-diene -3-one 
hERG  Human -ether a -go-go related gene, K v11.11 alpha subunit of 
potassium ion channel  
HIS Hachinski Ischemic Scale  
HOMA  Homeostatic model assessment  
HPA  hypothalamus -pi[INVESTIGATOR_2117] -adrenal  
HPLC  High -performance liquid chromatography  
Hsd17b4  17-hydroxysteroid dehydrogenase 4  
IFN interferons  
IB inhibitor of NF B 
IKK IB kinase  
IL interleukin cytokines  
IGT impaired glucose tolerance  
IQGAP1  IQ Motif Containing GTPase Activating Protein 1 scaffold  
IQR inter-quartile range  
IR Insulin resistance  
iv intravenous  
JNK c-Jun N -terminal kinases  
B promoter NF B transcription site  
KO Knock out  
KSR  kinase suppressor of Ras (scaffold)  
LC-MS-MS Liquid chromatography –tandem mass spectrometry  
LDL  Low-density lipoprotein  
LID L-dopa induced dyskinesia  
LPS lipopolysaccharide  
Lrp1  low density lipoprotein receptor related protein  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 9  
 
 Abbreviation  Definition  
MEK  mitogen -activated protein kinase kinase (phosphorylates ERK)  
MAP3K8  mitogen -activated kinase kinase kinase  (phosphorylates MEK; Tpl2 in 
mouse, COT1 in human)  
MAPK  mitogen -activated protein kinases  
MAPK1  p42 ERK2  
MAPK3  p44 ERK1  
MCI  Mild cognitive impairment  
MCP1  monocyte chemoattractant protein 1  
mITT  Modified Intent -to-Treat  
MPK1  mitogen -activated protein kinase phosphatase 1  
MMP  matrix metallopeptidases  
MMSE  Mini mental state exam  
MNK  MAP kinase signal -integrating kinase  
MP1  Mitogen -activated protein kinase  scaffold  protein 1  
MORG  WD-repeat protein family scaffold  
MPTP  1-methyl -4-phenyl -1,2,3,6 -tetrahydropyridine  
MRI  Magnetic resonance imaging  
mRNA  messenger ribonucleic acid  
MSK  stress -activated protein kinase  
MTD  Maximum tolerated dose  
M value  mean glucose infusion rate  
MW Molecular weight  
NE3107  17-ethynyl -androst -5-ene-3,7,17-triol 
NOAEL  No-observed -adverse -effect -level  
NEMO  NF-kappa -B essential modulator (aka IKK ) 
NFB nuclear factor kappa -light-chain -enhancer of activated B cells  
NMT  Not more than  
Nos Nitric oxide synthase  
NPI-12 Neuropsychiatric Inventory 12 -Domain  
p- phospho substituent (e.g. p -ERK)  
p38 p38 MAPK  
p65 NFB3 
p105  NFB subunit  
Paxillin  scaffold encoded by [CONTACT_575135]’s disease  
PD98059  MEK inhibitor  
PEA -[ADDRESS_754990]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754991], 
the time taken for ventricular depolarization and repolarization  
Raf serine/threonine -specific protein kinases  
Ras small GTPase proteins involved in signal transduction  
RAW264.7  mouse macrophage cell line  
RH Relative humidity  
Rsp6ka3  p90 ribosomal S6 kinases  
SAE  Severe adverse event  
Sef similar expression to fgf genes scaffold  
SIRT2  sirtuin -2 
SP1 specificity protein 1 (transcription factor)  
t1/[ADDRESS_754992]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 11  
 
 1 INTRODUCTION  
Considering how many people are in a state of mild cognitive impairment (MCI) and frank 
dementia, there is a substantial cost to society in terms of financial burden and suffering 
(Connolly, 2018). Degenerative conditions that result in cognitive change in middle and late 
life are frequently associated with abnormal deposits of protein material (e.g., amyloid, 
phospho -tau) which interfere with neuronal function and viability (Lacor, Buniel, Furlow, 
Clemente, Velasco, Wood, et a., 2007; Khan, 2016). Inflammation and insulin resistance in 
the CNS and abnormal protein deposition and resultant physiological impairment 
characterize con ditions of the Alzheimer’s dementia (AD) type (Kinney, Bemiller, 
Murtishaw, Leisgang, Salazar & Lamb, 2018; Rorbach -Dolata & Pi[INVESTIGATOR_269812], 2019).  
Neuroinflammation prompts AD progression, impaired cholesterol efflux and reduced insulin 
signaling (insulin resis tance) (Hølscher, 2020; Kinney et al., 2018; Rorbach -Dolata & 
Pi[INVESTIGATOR_269812], 2019; Chow, Shi & Cheng, 2019. Insulin resistance has been considered a risk 
factor as well as a feature of AD, and has also been associated with increased aß -42 
secretion, neuritic pla que burden, abnormal insulin receptor performance, decreased glucose 
metabolism, and consequently decreased cognitive performance (Holscher, 2020; Chow et 
al., 2019; Reading & Ahlem, 2021).  
No therapy exists that has been proven to halt or reverse the prog ressive deposition of 
abnormal proteins or the attendant neurophysiological deterioration. Various investigational 
therapi[INVESTIGATOR_575109]; from combating abnormal 
protein deposition, to targeting sources of systemic and neuroinflammation, to providing 
cholinergic, hormonal, and metabolic support. A promising area of research is the ongoing 
use of insulin synthesizers as a therapeutic option for AD. Several Phase [ADDRESS_754993] been 
initiated and/or completed with comp ounds such as Semaglutide, a hormone that stimulates 
insulin signaling (Nauck, Quast, Wefers, & Meier, 2020), Metformin, an insulin synthesizer 
(Koenig, Mechanic -Hamilton, Xie, Combs, Cappola, Xie, et al., 2017; Lin, Wang, Ma, 
Wang, Gong, Zhang, et al., 20 18), and NE3107, an anti -inflammatory insulin -sensitizing 
agent (Reading & Ahlem, 2021).  
In this study, the drug under investigation is NE3107 (17a -ethynyl0androst -5-ene-3b, 7b, 
17b-triol). NE3107 is a small, blood -brain permeable molecule with anti -inflammatory and 
insulin -sensitizing properties. The mechanism of action for NE3107 involves selective 
inhibition of inflammatory mediators.  
This study seeks to measure changes in advanced neuroimaging, CNS biomarkers of 
Alzheimer’s disease, inflammatory serological and metabolic parameters, and cogniti ve 
performance measures  among  participants  treated with NE3107 . 
The dose of NE3107 administered in this study will be [ADDRESS_754994]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 12  
 
 control and insulin sensitivity.  There has been no indication that NE3107’s anti -inflammatory 
activity could be increased with higher exposures. The dose duration will be 3 months. The 
rationale for 3 -month administration is to allow sufficient time for detectable change to 
occur. The ro ute of administration for NE3107 will be orally. NE3107 is formulated with 
common excipi[INVESTIGATOR_575110] #[ADDRESS_754995]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 13  
 
 2 STUDY OBJECTIVES  
2.1 Primary Objective(s)   
Primary endpoints will involve a comparison of neurophysiological health as evaluated by 
[CONTACT_7163] -modal brain MRIs obtained at baseline and post -intervention termination (3 months). 
Specifically, multi -modal MRI endpoints will include:  (1) An increase or stabilization in 
glutathione levels ( as measured by [CONTACT_156539], MRS) compared to 
baseline. Patients with cognitive decline often show characteristic change in MRS or 
volumetric evaluation compared to age -matched control s (Kuhn et al. 2021) ; (2) Stabilized 
and/or improved dendritic density compared to baseline (as measured by [CONTACT_575136], DTI -NODDI) ; (3) Enhancement of arterial signal compared to baseline (as 
quantified by [CONTACT_125840], ASL). Patients with cognitive decline often have 
decreased perfus ion in temporal parietal or frontal regions of the brain with ASL perfusion 
(Kuhn et al. 2021) ; (4) i ncreased functional connectivity of the nucleus basalis of Meynert 
(NBM) with both hippocampi [INVESTIGATOR_575111], as 
visualized by [CONTACT_575137] -oxygen level dependent (BOLD) imaging as well as (5) 
increased neurovascular coupling as visualized by [CONTACT_575138].   
 
2.2 Secondary Objective(s)   
Secondary endpoints will include a longitudinal comparison of me tabolic and serological 
analysis (specifically measures of glucose and insulin homeostasis); the level of cognitive 
impairment as defined by [CONTACT_6150] . Neuropsychological testing measures 
will include the Quick Dementia Rating Scale (QDRS) , Clinical Dementia Rating (CDR) 
score as estimated by [CONTACT_575139], the Alzheimer’s Disease Assessment Scale (ADAS -Cog12), 
the Mini -Mental State Examination (MMSE), and the Montreal Cognitive Assessment 
(MoCA).  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754996] are sufficiently prevalent so t hat recruitment 
of the projected numbers of participants  is not a limiting factor.  
 
The duration of treatment is 3 months. The rationale for 3 -month administration is to 
allow sufficient time for detectable change to occur. To minimize risk, participants  will 
be called within 24 hours following initiation of the drug and weekly thereafter, as well 
as attend monthly visits the principal investigator [INVESTIGATOR_575112]. Mild, moderate, and severe adverse reaction s will be reported 
on an ongoing basis.  Previously observed adverse reactions are listed in Table 22 of 
the Investigator’s Brochure. Participants  will be discontinued if they have moderate or 
severe adverse reaction ratings according to the ICH SAE E2A . 
 
(See Appendix 1, Study Events Table .) 
3.[ADDRESS_754997] an ordered dose response relationship across exposure on key indices of glycemic 
control and insulin sensitivity. There has  been no indication that NE3107’s anti -
inflammatory activity could be increased with higher exposures.   NE3107 
pharmacokinetics have high standard deviations for maximum serum concentration 
(Cmax) and daily area under curve (AUC), which raise the concern for drug holiday or 
suboptimal trough plasma concentrations in participants  with the lowest exposure.  The 
dose of [ADDRESS_754998] deviation below the average values for 10 mg B ID, with trough values 
greater than 1 ng/mL.   
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_754999]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 16  
 
 4 STUDY POPULATION SELECTION  
4.1 Study Popula tion 
Number of Participants  
 
Approximately 2 5 participants  are expected to be enrolled in this Phase II trial to 
evaluate longitudinal findings from multimodal MRI among the population that is 
being studied.  
 
Gender of Participants  
 
The gender distribution for this study will aim for a ratio of 50:[ADDRESS_755000] to be considered for this study, the following criterion is required:  
 
• Diagnosis of c ognitive decline due to degenerative dementia  
• Age within range of 50 -89 years old  
• QDRS score ranging from 1.5 -12.5, with a converted Clinical Dementia Rating 
(CDR) score of 0.5 (mild cognitive impairment) to 1(mild dementia)  
 
The QDRS scale w ill be given to all patients; a cutoff range for QDRS scores has been 
specified as 1.5 -12.5 to qualify patients with a clinical dementia score (CDR) of 0.[ADDRESS_755001] to be considered for this study, he/she may NOT  have any of the 
following:  
  
• Subjects with contraindications f or lumbar puncture, such as bleeding 
abnormalities, use of anticoagulant medications, and local skin or spi[INVESTIGATOR_575113] . See Section 6.6.1 “Laboratory Parameters,” page 26.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 17  
 
 • Subjects with contraindications to magnetic resonance imaging (MRI) 
acquisition, including patients with non MRI -compatible pacemakers, 
defibrillators, or other implanted electronic devices . 
• Women who are pregnant, who may become pregnant, or who are 
breastfeeding  
• Reversible causes of cognitive impairment that explains the clinical status 
entirely, such as hypothyroidism, depression  
• Advanced stages of any terminal illness or any active cancer that requires 
chemotherapy  
• History of breast cancer   
• Women with child -bearing potential who are not willing to use a double -barrier birth 
control method  
• Males not willing to use a double -barrier birth control method with female sex 
partners with child -bearing potential  
• Individuals with hepatic impairment as define d by: 
o Alanine aminotransferase (ALT) lab values >3x the upper normal limit (UNL)  
o Aspartate aminotransferase (AST) lab values >3x UNL  
OR 
o Histo ry of clinically significant liver disease in the Principal Investigator’s 
medical judgment  
• Individuals with renal impairment as defined by [CONTACT_575140] (Cockcroft -
Gault formula) of <45 mL/min.  
 
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 18  
 
 5 STUDY TREATMENT(S)  
5.1 Description of Treatment(s)  
5.1.1 Study Drug  
NE3107 is an investigational orally bioavailable, blood -brain barrier permeable anti-
inflammatory agent with a new mechanism of action targeting multiple mechanisms of 
pathology in Alzheimer's disease.  NE3107 is an  uncharged, low molecular weight molecule, 
poly-hydroxylated synthetic derivative of the C -[ADDRESS_755002] been conducted to measure membrane transport, active efflux/P -gp interaction, hepatic 
stability, CYP inhibition, and CYP induction.   
5.1.2 Placebo or Control  
All participants will receive the study drug; this study will utilize no placebo group.  
5.2 Treatment (s) Administered  
The drug under investigation is NE3107 (17a -ethynyl -androst -5-ene-3b,7b,17b -triol).  
NE3107 is formulated with common excipi[INVESTIGATOR_575110] #[ADDRESS_755003] gelatin 
capsules. The capsules are designed for oral administration.  The dose of NE3107 (Biovie, 
inc.) is 20 mg twice daily (BID) approximately 12 hour s apart , for the duration of 3 months. 
Study drug will be dispensed and monitored by [CONTACT_1034].  
5.3 Selection and Timing of Dose for Each Participant  
The dose of NE3107 (Biovie, inc.) is 20 mg twice daily (BID) approximately 12 hours apart. 
The dose will be s table for the duration of the study intervention , and will be the same for all 
participants.  
 
5.4 Method of Assigning Participants  to Treatment Groups  
All participants will receive active study drug at the same dosage.  
5.5 Blinding  
No blinding procedures will be utilized.  
5.6 Concomitant Therapy  
Concomitant medications will be considered any therapi[INVESTIGATOR_575114]/continues 
taking from the time point of [ADDRESS_755004]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 19  
 
 enzymes, so they do not factor into drug -drug PK interactions.  Donepezil is predomina tely 
metabolized by [CONTACT_097]2D6, but is also metabolized by [CONTACT_097]3A4.  NE3107 is also metabolized 
primarily by [CONTACT_097]3A4.  In conclusion, no drug -drug PK interactions with co -medications 
memantine, donepezil, galantamine and rivastigmine are expected with the propos ed dose of 
20 mg BID.  As noted in the exclusion criteria, patients with contraindications for lumbar 
puncture (such as bleeding abnormalities requiring the use of anticoagulant medications) will 
not be permitted into the study. Additionally, participants w ith any active cancer requiring 
chemotherapy will not be permitted to take part in the study.  
5.[ADDRESS_755005] no activity restrictions related to study involvement.  
5.8 Treatment Compliance  
Participants  / primary caregiver / study partner will be instructed to bring their unused 
investigational product (IP) to  every visit. Compliance will be assessed by [CONTACT_33315]. 
Details will be recorded in the case report form. All unused IP will be collected from the 
participant  at V10/ET. Noncompliance is defined as taking less than 80% or more than 120% 
of the assigne d dose during any outpatient evaluation period (visit to visit). Discontinuation 
for noncompliance is at the Investigator’s discretion . 
5.9 Packaging and Labeling  
Each investigational study drug will be labeled (in English) with a statement indicating that 
the drug is an investigational drug to be used only by a Qualified Investigator and will 
include but  not limited to: Drug Name, Strength, Protocol Number, Sponsor’s Name [CONTACT_13311], the recommended storage conditions for the drug, Expi[INVESTIGATOR_4061]/Retest Date (when 
available) and Lot/Batch Number.  
5.10 Storage and Accountability  
Records will be made of receipt and dispensing of NE3107  supplied.  It is the responsibility 
of the Sponsor to ensure that storage of study drug is within guidelines of the Investigator’s 
Brochure.  It is the responsib ility of the Manufacturer  to ensure that all drug supplies 
provided for the study are manufactured under current Good Manufacturing Practices 
(cGMP) and are suitable for human use.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755006]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 21  
 
 6 STUDY PROCEDURES  
For this Phase II open label study, all participants  will be screened following acquisition of a 
signed, wr itten informed consent form.  
Screening will involve confirmation that all inclusion criteria and none of the exclusion 
criterion are met. Following confirmation of inclusion and exclusion criterion, participants 
will undergo baseline testing to include th e following: Advanced magnetic resonance 
imaging ( MRI ) of the brain, lumbar puncture, APoE genotypi[INVESTIGATOR_007], cognitive testing, and 
serological analysis.  
All patients will have an advanced MRI of the brain to include T1 and T2 -weighted structural 
images, susceptibility -weighted imaging, neuromelanin, arterial spin labeling (ASL) 
perfusion, blood oxygen level -dependent (BOLD) at rest, diffusion tensor imagin g with 
neurite orientation density and dispersion (DTI -NODDI), and magnetic resonance 
spectroscopy (MRS) of the precuneus. MRI will demonstrate if patients have tumors, 
hydrocephalus, subdural hematomas and other structural etiologies of cognitive decline.  
Having the scan completed will be required for inclusion, but no specific imaging parameters 
will determine inclusion.  The advanced MRI of the brain will be repeated upon completion 
of the [ADDRESS_755007] APoE sw ab testing and a lumbar puncture for Aß42 and Tau proteins 
for Alzheimer’s Spectrum. This  spi[INVESTIGATOR_575115]’s disease. Cerebrospi[INVESTIGATOR_872] ( CSF) studies have 
demonstrated good sensitivity and specificity for mild cognitive impairment ( MCI ) and 
dementia of the Alzheimer’s type. MRI volumetrics, perfusion scans and MR spectroscopy 
have shown to be  responsive to change as patients progress from MCI t o dementia . The 
lumbar puncture is performed at  entry and after completion of the study protocol. The APoE 
testing will only be performed at baseline.  
 
Baseline and completion (3-month) cognitive testing will include the Quick Dementia Rating 
System (QDRS) , estimated clinical dementia rating (CDR) scale level, Mini -Mental Status 
Evaluation (MMSE), Montreal Cognitive Examination (MoCA), and Alzheimer’s Disease 
Assessment Scale (ADAS -Cog12). Upon completion of the protocol intervention, 
participants will also  be asked to report a Global Rating of Change (GRC) score in addition 
to the neuropsychological testing battery.  
 
All participants  will be administered the NE3107 and instructed to maintain a consistent 
daily dosage of [ADDRESS_755008] -intervention termination 
(3 months) (See 2.1: Primary Outcomes  and 2.2: Secondary Outcomes  for detailed 
descriptions of the MRI modalities and neuropsychological tests, respectively). Additional 
procedures include blood and serum samples to be collected at baseline and completion to 
ensure participant safety and effe ct of NE3107 on laboratory values (See 6.6.1 Laboratory 
Parameters ). 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755009]. All cons enting will be done behind closed doors in the privacy of a 
medical exam room. The participant  will be allowed to take home the consent form if he/she 
needs more time to review the document. The participant  will be read the consent form out 
loud by [CONTACT_575141]. As part of the study criteria, the 
participant  will be required to be cognitively aware and understand the English language. 
Therefore, the participant’s  consent should be viewed as their own, and without any undue  
influence or coercion. If the participant  feels uncomfortable, he/she may have an impartial 
witness of their choice enter the room for the consenting process.  
Before signing the consent form, the member of the study staff obtaining consent will 
verbally a sk the participant  if he/she has any questions regarding the consent form. If the 
participant  says no, the member of the study staff will ask if all information in the consent 
form was understood. If the participant  says yes, then a member of the study sta ff will ask if 
the participant  consents to being in this study. If the participant  says yes, he/she is ready to 
sign the consent form.  
The principal investigator, all sub -investigators, and the research coordinator may obtain 
consent from the participant . Once the participant  has agreed to be in the study and has 
signed the consent form, the documentation will exist both physically and electronically. The 
consent form will be scanned into a computer in which it will be stored under the appropriate 
folders d esignated for this research study. The computer will be locked under username, 
password, and firewall, and will only be accessible by [CONTACT_5984]. The physical version of 
the consent form will be stored behind lock and key in a drawer or cabinet design ated for this 
research study. The key will also only be accessible by [CONTACT_5984].  
 
6.2 Medical History  
Participants for the present study will be primarily recruited through the primary 
investigator’s medical practice. As patients, participants will have completed intake forms 
including medical history and any relevant neurological evaluations previously completed. 
All participants  will be  required to report on all previous medications  for 30 days prior to the 
study, as well as for the duration of the  study.  Memantine and acetylcholine esterase 
inhibitors, donepezil and rivastigmine, are permitted as co -medications in the proposed study.  
Per the Investigator’s Brochure, no drug -drug PK inter actions with co -medications 
memantine, donepezil, galantamine and rivastigmine are expected with the proposed dose of 
20 mg BID . As noted in the exclusion criteria, patients with contraindications for lumbar 
puncture (such as bleeding abnormalities requiri ng the use of anticoagulant medications) will 
not be permitted into the study. Additionally, participants with any active cancer requiring 
chemotherapy will not be permitted to take part in the study.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 23  
 
 6.3 Physical Examination  
The Principal Investigator (PI) and study doctor  will be responsible for performing physical 
examinations of the participants prior to study participation. As routine practice in the clinic, 
patients will have filled out a complete demographic questionnaire, undergone a physical 
examination at first vis it, and have had their vital signs recorded. The nervous system is the 
primary body system to be included in the examination  and routine demographics including 
height and weight will be noted.  
6.[ADDRESS_755010] or present medications.   
 
6.5 Electrocardiography and Continuous Telemetry Monitoring  
6.5.1 12-Lead Electrocardiograms  
ECG monitoring is not required during this study but may be requested  by [CONTACT_39635] . 
6.5.2 Continuous Holter Monitoring  
A continuous Holter monitor is not required during this study but may be requested  by [CONTACT_512340] . 
6.6 Clinical Laboratory Tests  
6.6.1 Labora tory Parameters  
Participant s will be in a seated  or supi[INVESTIGATOR_2526] . Clinical laboratory 
tests (to be collected at baseline, 2 weeks, 4 weeks, 8 weeks, and completion)  include  the 
following:  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 24  
 
  
Collected at Baseline and Completion:  
 
Hematology:  
- Complete Blood Count with 
Differential  
- Hematocrit (Hct)  
- Hemoglobin (Hgb)  
- Hemoglobin A1c  
- Mean corpuscular hemoglobin 
(MCH)  
- Mean corpuscular hemoglobin 
concentration (MCHC)  
- Mean corpuscular volume (MCV)  
- Platelet count  
- Red blood cell (RBC) count  
- White blood cell (WBC) count with 
differential  
 
Inflammatory Markers :  
- Appearance  
- Chlamydia pneumoniae serology 
(IgG/IgM)    
- TNF (tumor necrosis factor)   
- Cytokine Panel 13    
- hsCRP  (highly sensitive  c-reactive 
protein)   
- ESR (erythrocyte sedimentation 
rate)  
- HSV (herpes simplex virus 
serology, IgG/IgM)   
- CMV (cytomegalovirus serology, 
IgG/IgM)   
- Helicobacter pylori  - breath test   
- Lymphocyte Subset Panel 4:  CD4 
& CD8   
- Vasoactive intestinal peptide     
 
 
 
Serum Chemistry:  
- Albumin (ALB)  
- Alkaline phosphatase (ALK -P) 
- Alanine aminotransferase (ALT; 
SGPT)  
- Amylase  
- Aspartate aminotransferase (AST; 
SGOT)  
- Blood urea nitrogen (BUN)  
- Calcium (Ca)  
- Carbon dioxide (CO 2) 
- Chloride (Cl)  
- Creatinine  
- Creatine kinase and subtypes  
- Gamma -glutamyl transferase (GGT)  
- Globulin  
- Glucose  
- Lactate dehydrogenase (LDH)  
- Lipase  
- Phosphorus  
- Potassium (K)  
- Sodium (Na)  
- Total bilirubin  
- Direct bilirubin  
- Total protein  
- Triglycerides  
- Troponins  
- Uric acid  
- Zinc 
- Ethanolamine phospholipi[INVESTIGATOR_575116]3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 25  
 
 - TGF -b1  
- Alpha  Melanocyte stimulating 
hormone   
- Beta Melanocyte Stimulating 
Hormone    
- C4A   
- ACTH, 
Plasma  (Adrenocorticotropic 
hormone)   
- Anti-gliadin antibodies  
- VEGF   
- Gastrointestinal tract acids (GTAs)  
- MMP -9  
- Quantitative immunoglobulins   
- Lyme Antibody   
- Bartonella  quintana  antibodies  
 
Urinalysis, complete  
- Glucose  
- pH 
- Bilirubin  
- Ketones  
- Nitrite  
- Uric acid  
- WBC, RBC, epi[INVESTIGATOR_575117] 2, 4, and 8:  
- Amylase  
- Lipase  
- Potassium  
- Calcium  
- Complete Blood Count (CBC) with 
Differential  - Ethanolamine plasmalogens  
- DHA ethanolamine phospholipi[INVESTIGATOR_805]  
- Choline phospholipi[INVESTIGATOR_805]  
- Choline plasmalogens  
- DHA choline phospholipi[INVESTIGATOR_805]  
- Dietary fatty acids (omega -3, omega -
6, omega -9, OA, LA, AA)  
- Iron 
- Methyltransferase/choline system  
- Phosp hatidylethanolamines  
- Phosphatidylcholine  
- Sphingomyelins  
- Ceramides  
- Homocysteine  
- Elongase 5 activity  
- Peroxisomal function  
- DHA, EPA  
- Triacylglycerols  
- Cholesterol total  (Fasting)  
- HDL  (Fasting)  
- LDL  (Fasting)  
-  
 
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 26  
 
 - Hemoglobin A1c  
- Glucose  
- Alanine aminotransferase (ALT; 
SGPT)  
- Aspartate aminotransferase (AST; 
SGOT)  
- Creatine Phosphokinase  
- Cholesterol total  (Fasting)  
- HDL  (Fasting)  
- LDL  (Fasting)  
- Triglycerides (Fasting)  
 
Collected Prior to Lumbar Puncture 
Procedure:  
- Prothrombin time  
- International Normalized Ratio  
- Partial thromboplas tin time  
- Platelet count  
 
 
6.6.[ADDRESS_755011] Diagnostics, LabCorp, or any other  clinical  laboratory . Additional serum will be 
drawn at the primary study site and  sent for  analysis  to Prodrome Sciences ([ADDRESS_755012], Suite R, Temecula, CA [ZIP_CODE], [LOCATION_003] ). Samples will be shipped on ice and 
labeled adhering to federal biological substance shippi[INVESTIGATOR_132688].  
6.7 Dispensing Study Drug  
The Manufacturer  will supply sufficient quantities  of the study formulation for the following: 
(1) completion of this study and (2) retention, as per applicable regulations. All drug supplies 
provided for this study will be stored in a secure area with restricted access, under controlled 
storage condition s described in the product package labelling, unless otherwise instructed per 
protocol.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 27  
 
 Records will be made of receipt and dispensing of NE3107  supplied. It is the responsibility 
of the Manufacturer  to ensure that all drug supplies provided for the study  are manufactured 
under current Good Manufacturing Practices (cGMP) and are suitable for human use.  
 
6.8 Pharmacokinetic Assessments  
NE3107 is an orally bioavailable, blood -brain barrier permeable, uncharged, low molecular 
weight molecule (MW 330.46, LogD = 2), poly -hydroxylated synthetic derivative of the 
C-[ADDRESS_755013] been conducted to measure membrane 
transport, active efflux/P -gp interaction, hepatic stability, CYP inhibition, and CYP 
induction.  Numerous pharmacokinetics (PK) studies of NE3107 have been performed in 
various animal species using single and multiple doses exploring d ifferent routes of 
administration.  Oral NE3107 PK studies have been performed in mice, rats, rabbits, dogs, 
and monkeys.  PK following parenteral administration in support of absolute oral availability 
measurements has also been studied in mice and monkey s.  Numerous non -GLP PK studies 
have been conducted in mice to support formulation development, but only a few that are 
most relevant to the clinical drug product are summarized below.  GLP PK studies have been 
conducted in rats (Sprague Dawley) and dogs ( beagles) concurrent with toxicology studies.  
No stand -alone single dose GLP PK studies were conducted.  All GLP PK studies in rats and 
dogs have been conducted as part of multiple dose toxicology studies.  PK studies have been 
conducted in rat toxicology studies with oral gavage of NE3107 formulated as an aqueous 
solution in 30% sulfobutyl ether -cyclodextrin (formulation code HERF202) and as an 
aqueous suspension of micronized NE3107 (vehicle contained 1 mg/mL sodium 
carboxymethyl cellulose [CMC], 9 mg/mL sodium chloride, and 20 mg/mL polysorbate -80, 
0.5 mg/mL phenol (formulation code HERF405).  PK studies have been conducted in dogs 
with soluble NE3107 (HERF202) and with micronized NE3107 formulated in hard gelatin 
capsules containing sodium lauryl sulfate , polyplasdone XL 10, microcrystalline cellulose, 
and magnesium stearate in proportions similar to the NE3107 clinical capsule formulation 
used for all human studies.  NE3107 exists as a single polymorph in all lots of drug 
substance.  All PK studies of cr ystalline NE3107 used the same polymorph, which is the 
same polymorph used in human studies.  
6.9 Adverse Events Assessments  
Following all of  the inclusion/exclusion criteria may help to reduce the occurrence of severe 
adverse reactions. Both the principal investigator [INVESTIGATOR_9814] -investigators are medical doctors, 
and are licensed in the state of [LOCATION_004], and are in close communication the prim ary IND 
holder  (BioVie, Inc.)  regarding safety monitoring. We will be performing routine patient 
calls and standard monitoring of side effects due to these medications, as discussed 
elsewhere in this report. Following these guidelines, side effects can be identified early 
enough to mitigate any significant or permanent side effects.  
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 28  
 
 6.9.1 Timing  
NE3107 has no specific dose -limiting toxicity to guide stoppi[INVESTIGATOR_575118]. Abnormal lab values will be reviewed in the context of patient 
safety and potential relationship with NE3107 treatment and NE3107 prior safety data. The 
investigator may terminate a patient’s participation in the trial due to abnormal lab values 
irrespective the lab values potential relationship with NE3107 treatment.  
 
6.9.2 Severity  
The term "severe" describes the intensity (severity) of a specific event; the event itself, 
however, may  be of relatively minor medical significance (such as severe headache). This 
means it is not the same as "serious", which is based on patient/event outcome or action 
criteria usually associated with events that pose a threat to a patient's life or function ing.  
The severity of all AEs will be graded by [CONTACT_978]/Sub -Investigator or a medical qualified 
delegate according to the following 
definitions:  
Mild : Adverse event resulting in discomfort, but not sufficient to cause interference in 
normal daily activities.  
Moderate : Adverse event resulting in discomfort that is sufficient to cause interference in 
daily activities.  
Severe : Adverse event resulting in d iscomfort causing an inability to carry out daily 
activities.  
6.9.3 Relationship  
The PI/Sub -Investigator will assess the relationship of all adverse reactions to NE3107 using 
the following scale:  
Probable : A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to drug administration, unlikely to be attributed to concurrent disease or other drugs 
or chemicals, and which follows a clinically reasonable response on withdrawal.  
Possible : A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to drug administration, but which could also be explained by [CONTACT_63400]. Information on drug withdrawal may be lacking o r unclear.  
Unlikely: A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which makes a causal relationship improbable, and which 
other drugs, chemicals or underlying disease provide plausible explana tion.  

NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 29  
 
 Unrelated:  This category is applicable to AEs which are judged to be clearly and 
incontrovertibly due to extraneous causes (diseases, environment, etc.) and do not meet the 
criteria for drug relationship listed for the above -mentioned conditions.  
All AEs will be evaluated by [CONTACT_978]/Sub -Investigator, who must approve the subject for 
subsequent dosing.  
Any AEs, whether serious or non -serious, will be monitored throughout the study and 
followed to resolution, when possible, regardless of whether the s ubject is still participating 
in the study.  
6.9.4 Expectedness  
The principa l investigator and study doctor  will be responsible for determining whether an 
SAE is expected or unexpected as per drug labels. An adverse event will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the ri sk 
information previously described for the intervention.  
6.9.5 Clinical Significance  
Clinical laboratory data collected during the course of the study, which exceeds or drops 
below the acceptable limits for the participant population and which, based on baseline  
values, are considered by [CONTACT_16426], will be reported as an 
AE. If clinically significant abnormal laboratory values lead to, or are associated with clinical 
symptom(s), th ey will  be reported as an AE.  
6.9.6 Serious Adverse Events  
[IP_ADDRESS]  Definition  
A serious adverse event (SAE) is defined by [CONTACT_575142]: death, life -threatening AE, hospi[INVESTIGATOR_226526], a persi stent or significant disability/incapacity, or 
a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment,  
they may jeopardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse.  
[IP_ADDRESS]  Reporting Serious Adverse Events  
All serious adverse events (SAEs), whether or not the event is deemed study drug - related, 
will be reported to the Sponsor by [CONTACT_16470] [ADDRESS_755014]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755015] (IRB) and/or reported in accordance with local laws and regulations.  
6.10 Concomitant Medication Assessments  
Participant medications will be assessed by [CONTACT_976] [CONTACT_1629] d study staff upon initial screening for the 
study. Participants will be admitted as a patient under the PI [INVESTIGATOR_575119] a comprehensive 
demographics form (including past and present medications), which will be subsequently 
stored in the patient’s cha rt. Concomitant medications will be stabilized for [ADDRESS_755016] from trial participation for any of the following 
reasons:  
• A protocol violation occurs,  
• A serious or intolerable adverse e vent occurs,  
• A clinically significant change in a laboratory parameter occurs,  
• The sponsor or investigator terminates the study, or  
• The subject requests to be discontinued from the study.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 31  
 
 7 STUDY ACTIVITIES  
7.1 Screening Visit & Baseline Measure Collection (Days –10 to -1) 
Study Screening may take place during an initial visit with study staff to obtain the following 
assessments, which will be recorded in participant’s source documentation/medical record 
and on the Case Report Form ( CRF ): 
• Participant  ID number generation  
• Demographic information  
• Medical history  
• Vital signs  
• Height, weight, and calculation of BMI  
• Prior/concomitant medications  (must be stabilized for 30 days prior to study entry)  
• Quick Dementia Rating Scale (QDRS)  
• Clinical Dementia Rating (CDR) score, derived from QDRS  
• Confirming eligibility (no exclusionary criteria are met)  
Baseline measure acquisition may take place over the subsequent 9 days prior to starting the 
active study intervention, which will include the following:  
• Lumbar puncture to test for AB42 and Tau protein levels  
• APoE genotypi[INVESTIGATOR_007]  
• Advanced brain MRI  
o T1, T2, SWI, Neuromelanin, BOLD, ASL perfusion, DTI -NODDI, MRS of 
the precu neus 
• Cognitive examination including:  
o Montreal Cognitive Assessment (MoCA)  
o Mini -mental Status Examination (MMSE)  
o Alzheimer’s Disease Assessment Scale (ADAS -Cog12)  
• Blood tests for:  
o Complete blood count + diff  
o Creatinine clearance  
o Thyroid hormone panel  
o Elect rolytes  
o Inflammatory markers (hsCRP, TNFα, C D4, CD8, absolute neutrophils)  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755017] bilirubin  
o Hemoglobin  
• ProdromeScan blood test for:  
o Phosphatidylethanolamines  
o Choline  
o Mitochondrial function  
 
7.2 Clinic Admission (Day 0)  
On Day 0, each study participant will be provided with enough NE3107 capsules to maintain 
a 20mg bid dosage for the three -month active intervention period.  Participants will be 
instructed to take each dosage spaced approximately 12 hours apart.  
 
7.3 Treatment Period (Day 1 to Day 90)  
The drug under investigation is NE3107 (17a -ethynyl -androst -5-ene-3b,7b,17b -triol).  
NE3107 is formulated with common excipi[INVESTIGATOR_575110] #[ADDRESS_755018] 18 months. Stability of the capsules used i n this study will be 
monitored by a concurrent stability study conducted by [CONTACT_575143], Biovie, Inc (Santa Monica, CA).  
The rationale for 3 -month administration is to allow sufficient time for detectable 
change to occur. To minimize risk, participants  will be called within 24 hours following 
initiation of the drug and weekly thereafter, as well as meet with the study doctor 1 
week after starting the NE3107 regimen and attend ing once -monthly visits thereafter 
with the principal investigator [INVESTIGATOR_575120] . These visits will include evaluations 
of the following:  
 
• Vital signs  
• Height, weight, and calculation of BMI  
• Documenting  changes in concomitant medications  
• Participant reports of tolerability  
• Evaluation for AEs  
• Assessing compliance with the study drug  
 
Additionally, specific laboratory tests will be repeated at weeks 2, 4, and 8 to ensure 
safety ( 6.6.1 Laboratory Parameter s). Mild, moderate, and severe adverse reactions 
will be reported on an ongoing basis.  Previously observed adverse reactions are listed 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 33  
 
 in Table 22 of the Investigator’s Brochure. Participants  will be discontinued if they 
have moderate or severe adverse r eaction ratings according to the ICH SAE E2A .  
 
7.4 Early Termination Procedures  
Early termination assessments will include the full battery of neuropsychological testing, 
advanced MRI, and lumbar puncture to the extent that a participant is willing to undergo 
these follow -up assessments. The minimum assessment required for early termination is a 
clinical evaluation by [CONTACT_575144].   
 
7.5 Follow -up Visit (Day 90 ± 15)  
At the 3 -month follow -up visit, the following assessments will be performed and recorded in 
the participant’s  source documentation/medical record and on the CRF:  
• Vital signs  
• Weight  
• Conco mitant medications  
• AEs  
• Quick Dementia Rating Scale (QDRS)  
• Clinical Dementia Rating (CDR) score, derived from QDRS  
• Lumbar puncture to test for AB42 and Tau protein levels  
• Advanced brain MRI  
• T1, T2, SWI, Neuromelanin, BOLD, ASL perfusion, DTI -NODDI, MRS o f 
the precuneus  
• Cognitive examination including:  
• Montreal Cognitive Assessment (MoCA)  
• Mini -mental Status Examination (MMSE)  
• Alzheimer’s Disease Assessment Scale (ADAS -Cog12)  
• Blood tests for:  
• Complete blood count + diff  
• Creatinine clearance  
• Thyroid hormone panel  
• Electrolytes  
• Inflammatory markers (hsCRP, TNFα, CD4, CD8, absolute neutrophils)  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 34  
 
 • Quantitative immunoglobulins  
• Total and direct bilirubin  
• Hemoglobin  
• ProdromeScan blood test for:  
• Phosphatidylethanolamines  
• Choline  
• Mitochondrial function  
Note: NE3107 was not teratogenic in rat and rabbit safety studies. Sexually active male and 
female patients on study should continue using barrier method contraception for 72 hours 
(three days) after the last dose of NE3107 (terminal plasma t1/2 6 -8 hours). The out come of 
any pregnancy conceived by a patient on study will be followed to term and the results 
(normal or detailed description of abnormalities) will be collected as part of the study data 
and reported to the primary IND holder (Biovie, Inc,).  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755019] at their convenience. The Principal 
Investigator  (PI) and study staff will provide upon request source documents and/or other 
study -related documents. The PI [INVESTIGATOR_575121].  In addition, to ensure quality data and standardization, The Regenesis 
Project will send monthly status reports to BioVie Inc.  
All data will be recorded in accordance with good clinical practice ( GCP ) to ensure accuracy, 
completeness, legibility, and timeliness of the data reported. All data will be recorded 
directly on the source documents and will be considered source data. This  data will be 
transferred to Case Report Forms  (CRFs) . Source data and CRFs will be kept on site at The 
Regenesis Project. All records and documents pertaining to the study will be retained by [CONTACT_575145] (5) years from the comp letion of the study and will be 
available for inspection by [CONTACT_575146].  
All source documents and laboratory reports will be Quality Control reviewed to ensure 
accuracy and completeness. Adverse events will be reviewed and assessed for severity 
according to the ICH SAE E2A, dated [ADDRESS_755020]  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755021]. 
Software for statistical analyses will include Microsoft  Excel (version 14 or newer) and IBM 
SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., [LOCATION_003]).  Statistical  
analyses will be run to compare change from baseline at the post -intervention termination 
follow -up (three months after baseline) using a level of significance of 0.05.  
A single unblinded interim analysis may be performed when 30% to 50% of the participants  
have completed the final follow -up timepoint. The purposes of this interim analysis are to 
declare futility, study dis continuation for overwhelming efficacy, or sample size re -
estimation. The sample size will not be reduced based on interim data.  
The primary analysis model for the efficacy endpoints will be an MMRM analysis. All 
available data will be included in these m odels with no imputation for missing data. 
Supportive analyses of efficacy data may be conducted to evaluate different methods of 
handling missing data (i.e., Last Observation Carried Forward, Baseline Observation Carried 
Forward, multiple imputation for m issing data, etc.). The se supportive analyses will be 
detailed in the SAP.  Each endpoint within the neuropsychological testing family will be 
analyzed using MMRM analysis methods in a similar manner as to how the primary 
endpoints will be analyzed.  Formal significance for a given hypothesis will only be declared 
if that hypothesis is significant and all hypotheses within the family preceding it are 
significant. This approach will ensure strong type [ADDRESS_755022] are sufficiently 
prevalent so that recruitment of participants  is not a limiting factor  for the trial site . 
 
The sample size was chosen according to a power analysis calculated with 80% power 
and a significance level of 0.05. To achieve completion data for at least 20  participants , 
enrollment of 25 participants  will allow for 20% attrition while maintaining statistic al 
integrity.  
 
9.3 Analysis Populations  
Approximately 25 older adults (aged 50 -89 years)  are expected to be enrolled in th is Phase II 
trial to evaluate longitudinal findings from multimodal MRI . 
Populations to be analyzed in the study include the Full Analysis Population (all 
participants  who received any study drug and who participated in at least one post -
baseline assessmen t), Per Protocol Population (all participants  who adhere to the major 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 37  
 
 criteria in the protocol and who did not substantially deviate from the protocol), Safety 
Population (all participants  who received any study drug, excluding participants  who 
drop out pr ior to receiving any study drug). Evaluable participants  (those with baseline 
and completed follow -up data) will be included in final statistical analyses.  
 
Data may be excluded from analysis on the basis of participant  non-compliance with the 
protocol. Ou tliers will be identified by [CONTACT_575147][INVESTIGATOR_835]’s Criterion, Chauvenet’s 
Criterion, Grubb’s test for outliers, and Dixon Q’s test. If necessary to address outliers,  
the statistician will employ standard Winsorization techniques . 
 
The primary analysis  model for the efficacy endpoints will be an MMRM analysis. All 
available data will be included in these models with no imputation for missing data. 
Supportive analyses of efficacy data may be conducted to evaluate different methods of 
handling missing dat a (i.e., Last Observation Carried Forward, Baseline Observation 
Carried Forward, multiple imputation for missing data, etc.).  
 
9.[ADDRESS_755023] level (as derived from QDRS score) gathered at 
baseline and final follow -up (three months po st-baseline). Results may be stratified by [CONTACT_575148] a correlation  between baseline CDR and strength of clinical 
response.  
9.5 Statistical Analysis of Endpoints  
Based on published annual progression rates ranging from 15 -35%, the investigative team 
determined that this study subset could yield a proportional expected progression rate of 4 -
9% among study participants over the 3 -month study duration. (Maioli et al., 2007; McKann 
et al., 2011; Amieva et al., 2009; Mi tchell & Shiri -Feshki, 2009; Schmidtke & Hermeneit, 
2008;  Albert  et al., 2011; Mashour et al., 2019). Statistical analysis for primary and 
secondary endpoints will utilize standard evaluations for categorical data.  
Primary endpoints will involve a comparison of neurophysiological health as evaluated by 
[CONTACT_7163] -modal brain MRIs obtained at baseline and post -intervention termination (3 months). 
Specifically, multi -modal MRI endpoints will include:  An increase or stabilization in 
glutathione levels (as measured by [CONTACT_156539], MRS) compared to 
baseline. Patients with cognitive decline often show characteristic change in MRS or 
volumetric evaluation compared to age -matched control s (Kuhn et al. 2021) ; Stabilized 
and/or improved dendritic density compared to baseline (as measured by [CONTACT_575136], DTI -NODDI) ; Enhancement of arterial signal compared to baseline (as quantified 
by [CONTACT_125840], ASL). Patients with cognitive decline often have decreased 
perfusion in temporal parietal or frontal regions of the brain with ASL perfusion (Kuhn et al. 
2021) ; Increased functional connectivity of the nucleus basalis of Meynert (NBM) with both 
hippocampi [INVESTIGATOR_575111], as visualized by [CONTACT_575149] -oxygen level dependent (BOLD) imaging as wel l as increased 
neurovascular coupling compared to baseline.   
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 38  
 
  
9.5.1 Statistical Analysis for Primary Imaging Endpoints  
 
Repeated Measures ANOVAs (RMANOVAs) will be employed to evaluate whether the 
participants who successfully complete the treatment protoc ol demonstrate differential 
improvement in cognition over time with global and domain level mean T -scores as the 
outcome variable of interest. The same ANOVA -based statistical analysis paradigms will be 
applied to the neuroimaging data after it is preproce ssed. RMANOVAs will be run to 
determine whether the treatment group demonstrated improvements in the below imaging 
modalities, from baseline to study completion. Age, sex, and education, as statistically 
indicated, will be included as additional regressors . Correlation analyses  will then be 
conducted  to determine whether absolute change in domain level as measured by 
[CONTACT_575150]. To comp are individuals from the study 
population with a “normal” population, Z -score will be calculated for each individual for 
each component of the toolbox as well as compute a global -cognitive Z -score metric. This 
will allow the comparison of  individual  partic ipants  to a large population of normal derived 
from the published literature (e.g. Human Connectome Project).  
 
Global volumetric loss and regional atrophy is a common radiological finding related to AD 
progression. A disproportionate loss is expected in the temporal -parietal regions and 
hippocampal structures compared to age -matched controls in the study  
population  (Rabinovici  et al., 2007;  Whitwell et al., 2011).  T1 images will be corrected for 
field biasing. Then, using FMRIB’s Automated Segmentation Tool (FAST), T1 images will 
be skull -stripped and linearly registered to standard MNI space. Each patient’s T1 imag e will 
be segmented into [ADDRESS_755024] Cortical 
and Subcortical structural atlas in conjunction with  fslmaths. Mean volume will be computed 
for each of these regions for each patient with  fslstats  (Smith 200 2; Manera 2020).  The 
investigative team  will use  Freesurfer  version 6.0  (longitudinal recon -all function)  to obtain 
volumetric measures of 68 segmented cortical volumes and 70 cortical thicknesses.  Global 
volumetric loss and regional atrophy is a common ra diological finding related to AD 
progression.  Regional volumes will be analyzed (statistically  corrected for  intracranial 
volume) from baseline  – 3 months compared to age -match ed controls;  significant volumetric 
change is not expected to be seen over the c ourse of treatment with NE3107.  Nevertheless, 
additional  analyses will be conducted to determine if demographic or treatment variables 
predict change in regional volume. Correlation will assess the relationship between 
neuromelanin change and functional ou tcomes.   
 
Magnetic resonance spectroscopy (MRS) can detect biochemical changes in the brain related 
to loss of neuronal interactivity and other neurodegenerative pathology underlying dementia 
of the Alzheimer’s type (Graff -Radford & Kantaci, 2013). MRS dat a will be processed using 
Osirix (https://www.osirix -viewer.com/osirix/osirix -md/) and  Tarquin 
(http://tarquin.sourceforge.net/) to calculate neurotransmitter specific peak heights from 
which neurotransmitter comparison ratios (e.g. NAA/Gl) can be computed .  MRS values will 
be creatine adjusted to improve the likelihood that data was derived from tissue and not CSF. 
Literature consistently reports on a ratio of decline between the NAA and Creatine (Cr) peaks 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 39  
 
 among patients with AD  (Modrego & Fayed, 2011).  A Wilcoxon Signed -rank test will be 
performed in R (https://www.rstudio.com/)  to statistically analyze the changes in the 
NAA:Cr ratio from baseline to completion of NE3107 protocol. In addition, glutathione 
levels decrease with redox stress, and declines i n glutathione levels have been reported on 
among patients with AD  (Mandal, Saharan, Tripathi & Murari, 2015b) . It is anticipate d that 
participants will demonstrate improvement (elevation) of glutathione levels compared to 
baseline as a signal of overall im provement in bioenergetics. Glutathione levels after NE3107 
intervention will be compared to baseline levels with a Wilcoxon Signed rank test in R. 
Correlation will assess the relationship between neuromelanin change and functional 
outcomes.  
 
Noradrenergic  dysfunction  has been  associated with the  cognitive decline  seen 
in Alzheimer’s  disease  (Peterson  & Li,  2018).   Pathological  alteration to the locus coeruleus,  
a major source of noradrenaline in the brain, has  been  implicated  in neurodegenerative 
process es (Betts, Kirilina,  Otaduy, Ivanov, Acosta -Cabronero, Callaghan, et al.,  2019).  Locus 
coeruleus  integrity can be assessed by [CONTACT_575151] a Neuromelanin -
sensitive MRI.  Decreased signal  intensity  in the locus coeruleus  is expected as dement ia 
progresses  (Olivieri,  Lagarde,  Lehericy,  Valabrègue, Michel, Macé  et al., 
2019).  Longitudinal changes in  locus coeruleus  signal  will be evaluated  visually  by 
a blinded  neurologist.  Participant change will be analyzed relative to expected rates of 
dropou t/loss.  Correlation will assess the relationship between neuromelanin change and 
functional outcomes.   
  
By [CONTACT_575152] -water changes and the integrity of white matter tracts, DTI can indirectly 
measure changes caused by [CONTACT_575153]  (Wen , Risacher, Xie, Li, Harezlak, 
Farlow et al.,  2021; Alexander , Lee, Lazar & Field,  2007 ; Smith, Johansen -Berg, Jenkinson, 
Rueckert, Nichols, Miller et al., 2007).  The post-NE3107 DTI metric [fractional anisotropy 
(FA) and mean, axial and radial diffusivity (MD, AD, RD)] image  will be subtracted  from 
the baseline image to produce  change images  (Fu, Shrestha, Sun, Wu, Luo, Zhang, et al., 
2019).  Neurite orientation dispersion and density imaging (NODDI) uses a three -
compartment model to probe brain tissue microstructure: (1) Free Water Fraction (FWF) 
which estimates the extent of  CSF contamination, (2) Neurite Density index (NDI) which 
quantifies the packing density of axons/dendrites, and (3) Orientation Dispersion index (ODI) 
which assesses the coh erence of neurites  (Fu et al., 2019;  Zarei , Patenaude, Damoiseaux, 
Morgese, Smith, Matthews et al.,  2010).   
 
Limited literature using NODDI has been produced in -vivo in mild -cognitive impairment 
subjects, but the current results show it to be more sensitive/robust than traditional FA 
values  (Fu et al., 2019). Similar to ASL, the  three  indexes will be compared bet ween 
baseline/follow -up values. It would be  expect ed that  an increase in NDI and a decrease in 
ODI/FWF to correspond with an improvement in brain health  (Fu et al., 2019).  Here,  an 
established tract -based spatial statistics (tbss) approach will be used to assess the relationship 
between voxel -wise changes in white matter integrity  (Fu et al., 2019).  Additionally, graph 
theory will be applied to quantify the effect of NE3107 on hippocampal connectivity and 
associate this effect with  cross -sectional and longi tudinal cognitive performance  (Wen  et al., 
2021).  Lastly,  probabilistic tractography will be used to simulate white matter connectivity 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 40  
 
 between the hippocampus formations  (Zarei  et al., 2010)  and Nucleus  Basalis of  Meynert. 
The baseline and follow -up will similarly be compared.  Again, RMANOVA will 
compare  pre-and post-NE3107 treatment and within group analyses will assess network 
predictors of response to NE3107 treatment. All imaging analyses will be corrected for 
multiple comparisons, both across voxel an d between analyses.   
 
Arterial Spin Labeling (ASL) data will be processed and analyzed using FSLs Bayesian 
Inference for ASL MRI (BASIL ; Chappell, Groves, Whitcher & Woolrich, 
2009;  Woolrich,  Chiarelli,  Gallichan,  Perthen  & Lie,  2006 ).  ASL scans yield  a perfusion 
image with voxel values representing local perfusion rates; perfusion difference will be 
calculated (subtracting tagged/control pairs) and averaged to create a mean perfusion -
weighted image  (Chen,  Wolk & Reddin,  2011 ). Quantification to cerebral b lood flow (CBF) 
values (milliliters of blood per 100 g of tissue per minute) will be implemented using an 
estimate of the equilibrium magnetization of arterial blood and the mean perfusion values  
(Ahlgren,  Wirestam, Knutsson & Petersen,  2018;  Hernandez -Garcia & Jahanian,  2010) . 
Given the variability of ASL across patients , CBF data will be examined as a ratio to mean 
grey matter signal.  
 
Each participant’s  ASL data will be linearly to each his or her T1-weighted image ; images 
will then be transferred to MN I space using non -linear registration in FSL. Within FSL , a 
voxel -wise between groups (normal vs MRI) comparison of perfusion, corrected for multiple 
comparisons , will be performed . A repeated measures comparison within subject for pre -vs 
post intervention  ASL as well as between group s will be used to compare effects of NE3107 
to normals.  Demographic covariates will be included in the model as indicated.  All imaging 
analyses will be corrected for multiple comparisons, both across voxel and between analyse s. 
 
Existing literature consistently demonstrates a dropout of signal seen in the temporal parietal 
lobes among individuals with dementia of the probable Alzheimer’s type  (Zhang, Gordon & 
Goldberg, 2017) . The  mean  perfusion values per voxel in the temporal parietal regions  will 
be measured and used to  generate a statistical output of participant values relative to a 
normative, age -matched database. This will test  the hypothesis that there will be either 
stabilizati on or improvement of voxel signal among participant scans compared with the 
normative database associated with NE3107.  
 
Reported trends in BOLD imaging follow dementia progression from earlier stages of decline 
(e.g., CDR = 0.5, characterized by [CONTACT_575154] h ippocampal hyper connectivity) to progressive 
stages of dementia (CDR > 1) and ultimate loss of hippocampal connectivity  (Wang, Zang, 
He, Liang, Zhang, Tian et al., 2006; Sperling, 2011) . Processing of resting state  (rs) fMRI 
will include correcting for mot ion artifacts (using framewise displacement calculations, and 
within -subject independent component analysis), scrubbing, unwarpi[INVESTIGATOR_575122] (FWHM = 5mm). rsFMRI data will be linearly registered to stereotaxic MNI 
space and co -registered with a natomic, T1 data for each participant.  
 
Two approaches will be used t o test rs -network differences. First, the hub of the default mode 
network atlas will be used as a seed region for each subject , and multivariate exploratory 
linear optimized decompositio n into independence components (MELODIC)  will be used  to 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 41  
 
 identify the brain regions whose time series correlate significantly with the hub  (Erhardt, 
Rachakonda, Bedrick, Allen, Adali & Calhoun, 2011) . Between -groups comparison of these 
correlation maps wil l identify differences in default and salience network integrity. A matrix 
for each subject will then be made from correlations of time series between each node.   
 
Subsequently, ANOVA will be used to assess group comparisons of the connection strength 
between nodes, within networks and between networks. All of these analyses will be 
conducted both within diagnostic group (e.g. within healthy control group only) and between 
diagnostic groups (i.e. compare effects in cognitive impairment and control groups).  Finally, 
time series correlation s will be assessed  between multiple regions of interest implicated in 
the literature in Alzheimer’s disease (hippocampal formation, Nucleus Basalis of Meynert 
(NBM), and other seeds) and the rest of the brain to generate fu nctional connectivity maps  
(Salami, Pudas & Nyberg, 2014; Li, Jia, Qi, Fan, Ma, Ni et al., 2017; Miao, Wu, Li, Chen & 
Yao, 2011) . Then, between -group comparison will identify differences in the 
connectivity/network integrity of these regions. Finally, with in-group regressions will be 
used to determine which neural network factors predict response to NE3107 treatment.  Age, 
sex, education, and neuropsychological assessment, as needed, will be included as additional 
regressors. All imaging analyses will be co rrected for multiple comparisons, both across 
voxel and between analyses.  
 
For the seed -based analysis, after spatial normalization of the images, a standard ROI of the 
bilateral hippocampi [INVESTIGATOR_575123] a priori anatomic segmentation. A 
seed reference time course will be obtained by [CONTACT_575155]. Correlation analyses will be carried out between the seed reference and the whole brain 
in a voxel -wise manner. The percent signal change will be extracted  from within the same 
ROI across multiple scan acquisitions and compare an individual’s change relative to 
expected levels of change. Existing literature suggests that a relatively higher activation of 
hippocampal activity precedes a steeper slope of cogni tive decline. Individuals with a 
baseline CDR  of 0.[ADDRESS_755025] loss of 
hippocampal activation over time  (O’Brien, O’Keefe, LaViolette, DeLuca, Blacker, 
Dickerson, & Sperling, 2010) . We will compare between baseline, pre -NE3107 and post -
NE3107.  
 
Further, BOLD -activity changes will be assessed within a standard ROI (e.g., hippocampus; 
conventionally defined using a priori anatomic segmentation).  To do so, the percent signal 
change within the same ROI across multiple scan acquisitions will be extracted to  compare 
an individual  participant’ s change relative to expected levels of change. The degree of this 
change will be correlated with NE3107 treatment and other neural network and behavioral 
changes to further elucidate the intricacies of the NE3107 treatment. A decrease in 
neurov ascular coupling  is expected  (as shown and evaluated voxel -wise) globally and 
regionally in the locus coeruleus and temporal parietal lobes compared to age -matched 
controls. With NE3107 intervention, it is hypothesize d that participants will yield 
improvem ent in neurovascular response from baseline. This will be analyzed  relative to the 
normative database and expected decline.  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 42  
 
 9.5.2  Statistical Considerations for Secondary Endpoints  
Secondary endpoints will include a longitudinal comparison of metabolic and serological 
analysis (specifically measures of glucose and insulin homeostasis); the level of cognitive 
impairment as defined by [CONTACT_6150] (QDRS/CDR, MMSE, ADAS -Cog, and 
MoCA scores). Thresholds for reporting clinically meaningful change will include references 
to published minimal clinically important differences (MCIDs) for each measure.  Paired 
samples t -tests will be used to statistically analyze each secondary e ndpoint, including the 
cognitive measures described below as well as changes in serological markers.  
The ADAS -Cog evaluates participants’ cognitive abilit ies. It is composed of [ADDRESS_755026]/figure naming, command following, co nstructional praxis, 
ideational praxis, orientation, word recognition, test direction recall, spoken language, 
comprehension, and word -finding difficulty. The ASAS -COG is scored from [ADDRESS_755027] severe 
impairment. A point reduction of 3.1 to 3.8 has been found to be the minimal clinically 
important difference (Schrag & Schott, 2012).  
The MMSE is a 30 -point questionnaire that evaluates cognition. The MMSE includes 
specific tasks tha t assess orientation, attention, memory, language and visual -spatial skills. 
MMSE scores range from 0 – 30 possible points; 0 -17: severe cognitive impairment, 18 -23: 
mild cognitive impairment, 24 -30: no cognitive impairment. A point decrease >/= to 3 on th e 
MMSE has been identified as the minimally clinically important difference (Andres, 2019).  
The MoCA evaluates frontal -executive functions (e.g., verbal abstraction and mental 
calculation), language (e.g., confrontation naming, phonemic fluency), orientati on (e.g., 
person, place, date, day of the week, and time), visuospatial construction (e.g., simple figure 
copy), divided visual attention, and immediate and delayed memory of unstructured 
information  (Nasreddine, Phillips, Bédoran, Charbonneau, Whitehead, Collin, et al., 2005) . 
MoCA scores range from 0 -30 possible points; [ADDRESS_755028] normal 
cognitive status.  
The Quick Dementia Rating Scale (QDRS) is an interview -based tool administered by [CONTACT_575156]' caregiver s used to obtain observations from a consistent source  
(Berman , Koscik, Clark, Mueller, Bluder, Galvin et al., 2017) . The QDRS form consists of 
10 categorical questions (5 cognitive, 5 functional), each with 5 detailed options depi[INVESTIGATOR_575124] 0 (normal), 0.5 (mild/inconsistent impairment), 1 
(mild/consistent impairment), 2 (moderate impairment), or 3 (severe impairment). Based on 
the conversion table outlined in [CONTACT_575169]'s research (2015), total QDRS scores were 
converte d to Clinical Dementia Rating (CDR) scale levels ranging from 0 (normal aging), 0.5 
(mild cognitive impairment), 1 (mild dementia), 2 (moderate dementia), and 3 (severe 
dementia).  
9.6 Safety Analysis  
Mild, moderate  and severe adverse effects/reactions and mortality will be monitored to 
confirm the safety and tolerability of NE3107 in the study population. Blood tests and 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755029] of the 
primary IND holder (Biovie, Inc.) as required under 21 CFR 312.32(c)(1)(v). These reports 
will be recorded in a lab notebo ok that will be locked away in a cabinet requiring a key that 
only the study staff will have access to. This information will also be transcribed to a 
computer file that will be kept behind username [CONTACT_2383].  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 44  
 
 10 ADMINISTRATIVE CONSIDERATIONS  
10.1 Investigators  and Study Administrative Structure  
Principal Investigator:  [INVESTIGATOR_575125] E. Jordan, MD  
Sheldon Jordan MD, Inc.  dba The Regenesis Project  
[ADDRESS_755030]., S uites #690 & 790, Santa Monica, CA [ZIP_CODE]  
Phone number: (310) [ADDRESS_755031]  (IRB) Approval  
Prior to study initiation, institutional review board (IRB) approval shall be obtained  and 
proof shall be provided to all regulatory agencies. The IRB submission for NE3107 -TRP-001 
“A Phase II Open Label Study for the Use of Anti -Inflammatory, Insulin Sensitizing NE3107 
for the Treatment of Cognitive Decline Due to Degenerative Dementias” i s awaiting final 
review and approval from Advarra IRB  (Pr#00058626) . All reviews and approval by [CONTACT_575157] (GCP).   
In the event of any serious adverse events, the IRB will be notified by [CONTACT_4530].  
10.[ADDRESS_755032] their origin in the Declaration of Helsinki. The wri tten informed 
consent form and any other written information provided to participants  will be revised 
whenever new information becomes available that may be relevant to the participant’s  
consent. Any revised written informed consent form and written inform ation will receive 
IRB approval in advance of use. Neither the investigator, nor the study staff, will coerce or 
unduly influence a patient  to participate or continue participation in a trial.  All consenting 
will be done behind closed doors in the privacy of a medical exam room. The participant  will 
be allowed to take home the consent form if he/she needs more time to review the document. 
The participant  will be read the consent form out loud by [CONTACT_575158]3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 45  
 
 obtaining consent. As part of th e study criteria, the participant  will be required to be 
cognitively aware and understand the English language. Therefore, the participant’s  consent 
should be viewed as their own, and without any undue influence or coercion. If the 
participant  feels uncomfortable, he/she may have an impartial witness of their choice enter 
the room for the consenting process.  
 
Before signing the consent form, t he member of the study staff obtaining consent will 
verbally ask the participant  if he/she has any questions regarding the consent form. If the 
participant  says no, the member of the study staff will ask if all information in the consent 
form was understoo d. If the participant  says yes, then a member of the study staff will ask if 
the participant  consents to being in this study. If the participant  says yes, he/she is ready to 
sign the consent form.  
As stated in the Process of Consent section, all consent by  [CONTACT_575159] a private medical exam office. Once the participant  has agreed to be in the 
study and has signed the consent form, the documentation will exist both physically and 
electronically. The consent form will b e scanned into a computer in which it will be stored 
under the appropriate folders designated for this research study. The computer will be locked 
under username, password, and firewall, and will only be accessible by [CONTACT_5984]. The 
physical version of the consent form will be stored behind lock and key in a drawer or 
cabinet designated for this research study. The key will also only be accessible by [CONTACT_8702].  
10.[ADDRESS_755033] of 1996 and its implementing regulations (HIPAA) with respect to the 
collection, use, storage, and disclosure of Protected Health Information (PHI) as defined in 
HIPAA. All study -related PHI shall be collected, stored, used, accessed, and disclosed only 
as permitted by [CONTACT_1201] -approved informed consent form or HIPAA authorization form 
obtained from a study participant . BioVie’s ability to review participants’  study -related 
information contained in the study participan ts’ medical records shall be subject to 
reasonable safeguards for the protection of study participant  confidentiality and  the study 
participants’  informed consent forms or HIPAA authorization forms. BioVie shall not 
attempt to identify, or contact, any Study participant  unless permitted by [CONTACT_575160].  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755034]. Jordan is on staff at Providence Saint John’s Medical Center which 
is within one to two miles of the clinical site of Sheldon Jordan MD, Inc. dba The Regenesis 
Project at  [ADDRESS_755035] -processed neuroimaging data, and screening  forms. Data from source 
documents will be transferred to case report forms (CRFs) using anonymized participation  
identification numbers. CRF forms are created and modified by [CONTACT_575161]. 
The Principal Investigator [INVESTIGATOR_575126] -monitoring reports related to the study; all of which will be submitted to the 
IRB as required. During the study and for at least two years following the completion of the 
study at all sites, the stu dy staff and Principal Investigator [INVESTIGATOR_575127], including study results and any routine monitoring 
findings, monitoring reports, and data safety monitoring committee reports including, but not 
limited to, data and safety analyses, and any study information that may (a) affect the safety 
and welfare of current or former study participants , or (b) influence the conduct of the study.  
10.8 Protocol Violations/ Deviations  
Deviations from the protocol which will be con sidered protocol violations include late “out -
of-window” follow -up telephone and in -person visits  and missed testing appointments. These 
deviations will be reported in the final clinical study report.  
10.[ADDRESS_755036] following 
completion of the study protocol.  
The study site acknowledges that trial -related monitoring audits , regulatory inspection(s), and 
regular IRB review are expected, and will make direct access to source data and documents 
available for review by [CONTACT_575162].  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755037]. Both physical and digital data will only be 
accessible by [CONTACT_16133].  
 
The clinical database will be generated using Microsoft Excel (version 14 or newer) and 
analyzed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., 
[LOCATION_003]).  
Data will be entered by [CONTACT_575163] a weekly basis. Database entries 
will be checked for ac curacy and completion at the time of internal audits, to be performed at 
a minimum of twice per month throughout the study.  
10.11  Retention of Data  
The study staff shall retain and preserve a copy of the study records for the longer of (a) five 
(5) years following the termination of the study protocol . 
10.[ADDRESS_755038] of 2010, 
provided that the disclosure clearly designates the payment as having been made to the 
Sponsor Institution (The Regenesis Project) and not to t he Principal Investigator [INVESTIGATOR_575128].  
10.[ADDRESS_755039] to publications of any study data, the contents (including scientific conclusions 
and professional judgments) of any paper submitted shall be determined by [CONTACT_9532] [INVESTIGATOR_575129]. The Principal Investig ator shall provide 
the Sponsor with a copy of papers prepared for publication at the earliest practicable time, 
but in any event not less than sixty (60) days prior to the submission to a scientific journal or 
presentation at scientific meetings and a reas onably detailed summary or abstract of any 
other oral or written publication not less than sixty (60) days prior to their submission or 
presentation. The investigative team shall consider any and all comments made by [CONTACT_575164]; BioVie personnel shall be acknowledged in accordance with customary scientific 
practice; authorship shall be determined in accordance with the standards of the International 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 48  
 
 Committee of Medical Journal Editors (ICMJE). If during BioVie’s review, BioVie finds that 
any publ ication contains BioVie Confidential Information, BioVie shall have thirty (30) days 
from the date of receipt from the investigative team to respond with a request to remove such 
Confidential Information . The Principal Investigator [INVESTIGATOR_575130]’s support of the study, and if 
applicable, support of the development of the publication or disclosure. BioVie shall be 
entitled to make and use copi[INVESTIGATOR_575131]. The sixty (60) day minimum lead time for publication or disclosure may 
be shortened by [CONTACT_575165].  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755040]  
Connolly, S. (2018). Economics of dementia: A review of methods. Dementia, 
147130121880063.doi:10.1177/1471301218800639   
Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., V iola, 
K.L., & Klein, W.L. (2007) Aß oligomer -induced aberrations in synapse composition, shape, 
and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J 
Neuroscience, 27(4):796 -807. doi: 10.1523.JNEUROSCI.3501 -06.2007.  
Khan,  T.K. (2016) Chapter 1 – introduction to Alzheimer’s disease biomarkers. Biomarkers 
in Alzheimer’s Disease, pp. 3 -23. doi:10.1016/B978 -0-12-804832 -0.[ZIP_CODE] -8 
Chen M.J., Ramesha S., Weinstock L.D. et al. (2021) Extracellular signal -related kinase 
regulates m icroglial immune responses in Alzheimer’s disease. J Neurosci Res. 
Doi:10.1002/jnr.[ZIP_CODE]  
Lonskaya, I., Hebron, M., Chen, W., Schacter, J., & Moussa, C. (2014) Tau deletion impairs 
intracellular beta -amyloid -42 clearance and leads to more extracellular plaq ue deposition in 
gene transfer models. Mol Neurodegener; 9(46). doi:10.1186/1750 -1326 -9-46 
Skaper, S.D. (2017) Chapter 2 – Impact of inflammation on the blood -neural barrier and 
blood -nerve interface: from review to therapeutic preview. International Revie w of 
Neurobiology, 137. pp. 29 -45. doi:10.1016/bs.irn.2017.08.004  
Kinney J.W., Bemiller S.M., Murtishaw A.S., Leisgang, A.M., Salazar, A.M., & Lamb, B.T. 
(2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement, 4: 
575-90. 
Rorb ach-Dolata A. & Pi[INVESTIGATOR_269812] A. (2019) Neurometabolic evidence supporting the 
hypothesis of increased incidence of Type [ADDRESS_755041] century. Biomed 
Res Int. 1435276  
Hölscher, C. (2020) Brain insulin resistance: role in neurodegenerative dise ase and potential 
for targeting. Expert Opi[INVESTIGATOR_194444] , 29(4): 333 -48. doi: 
10.1080/13543784.2020.1738383  
Chow H.M., Shi M., & Cheng A. (2019) Age -related hyperinsulinemia leads to insulin 
resistance in neurons and cell -cycle -induced sen escence. Nat Neurosci, 22(11): 1806 -19. 
Reading C.L., Ahlem, C.N., & Murphy, M.F. (2021) NM101 phase III study of NE3107 in 
Alzheimer’s: rationale, design and therapeutic modulation of neuroinflammation and insulin 
resistance. Neurodegener. Dis. Manag. doi :10.2217/nmt -[ADDRESS_755042] D.R., Wefers, J, Meier, J.J. (2020) GLP -1 receptor agonists in the 
treatment of type 2 diabetes – state-of-the-art. Mol Metab 46:101102. 
Doi:10.1016/j.molmet.2020.[ADDRESS_755043]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 50  
 
 Koenig, A.M., Mechanic -Hamilton, D., Xie, S. X., Combs, M.F., Cappola, A.R., Xie, L., 
Detre, J.A., Wolk, D.A., & Arnold, S.E. (2017) Effects of the insulin sensitizer metformin in 
Alzheimer disease: pi[INVESTIGATOR_26923] a randomized placebo -controlled crossover study. 
Alzheimer Dis Assoc Disord, 31(2)  
Lin, Y., Wang, K., Ma, C., Wang, X., Gong, Z., Zhang, R., Zang, D., & Cheng, Y. (2018). 
Evaluation of metformin on cognitive improvement in patients with non-dementia vascular 
cognitive impairment and abnormal glucose metabolism. Frontiers in aging neuroscience , 
10, 227. https://doi.org/10.3389/fnagi.2018.[ZIP_CODE]  
Kuhn, T.P., Becerra, S.A., Duncan, J.D., Mamoun, M., Whitney, M., Pereles, S., By[CONTACT_67002] , 
A., & Jordan, S.E. (2021) Translating state -of-the-art brain MRI techniques into clinical 
practice: clinical utility validation of multimodal neuroimaging pi[INVESTIGATOR_575132]. Quantitative Imaging in Medicine & Surgery, 11(9): 4056 -4073. doi: 
10.[ZIP_CODE]/qims -20-1355  
Adamczuk, K., Schaeverbeke, J., Vanderstichele, H.M., Lilja, J., Nelissen, N., Laere, K.V., 
Dupont, P., Hilven, K., Poesen, K., & Vandenberghe, R. (2015) Diagnostic value of 
cerebrospi[INVESTIGATOR_872] Aß ratios in preclinical  Alzheimer’s disease. Alzheimer’s Research & 
Therapy. 7:75. doi:10.1186/s13195 -015-0159 -5. 
Maioli, F., Coveri, M., Pagni, P., Chiandetti, C., Marchetti, C., Ciarrochi, R., Ruggero, C, 
Nativio, V., Onesti, A., D’Anastasio, C., & Pedone, V. (2007) Conversion  of mild cognitive 
impairment to dementia in elderly subjects: A preliminary study in a memory and cognitive 
disorder unit. Archives of Gerontology and Geriatrics, 44: 233 -41. 
doi:10.1016/j.archger.2007.01.032  
 
McKhann, G.M., Knopman, D.S., Chertkow, H., H yman, B.T., Jack, R.C., Kawas, C.H., 
Klunk, Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., 
Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., & Phelps, C.H. (2011) The diagnosis 
of dementia due to Alzheimer’s diseas e: recommendations from the National Institute on 
Aging -Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s 
disease. Alzheimer’s & Dementia, 7: 263 -9. doi:10.1016/j.alz.2011.03.005  
Amieva, H., Letenneur, L., Dartigues, J -F., Rouch -Leroyer, I., Sourgen, C., D’Alchée -Birée, 
F., Dib, M., Barberger -Gateau, P., Orgogozo, J. -M., & Fabrigoule,  C. (2009) Annual rate 
and predictors of conversion to dementia in subjects presenting mild cognitive impairment 
criteria defined according to a popu lation -based study. Dementia and Geriatric Cognitive 
Disorders, 18:87 -93. doi: 10.1159/000077815  
Mitchell, A.J. & Shiri -Feshki, M. (2009) Rate of progression of mild cognitive impairment to 
dementia - meta -analysis of [ADDRESS_755044] inception cohort studies. Ac ta Psychiatria 
Scandinavica, 119(4):252 -65. doi:10.1111/j.1600.0447.2008.[ZIP_CODE].  
Schmidtke, K. & Hermeneit, S. (2008) High rate of conversion to Alzheimer’s disease in a 
cohort of amnestic MCI patients. International Psychogeriatrics, 20(1): 96 -108. 
doi:10. 1017/S1041610207005509  
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-[ADDRESS_755045], W.J., Peterson, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., & 
Phelps, C.H. (2011) The diagnosis of mild cognitive i mpairment due to Alzheimer’s disease: 
recommendations from the National Institute on Aging -Alzheimer’s Association workgroups 
on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7:270 -9. 
doi:10.1016/j.jalz.2011.03.008.  
Mashour, G.A., Frank, L., Batthynany, A., Kolanowski, A.M., Nahm, Schulman -Green, D., 
Greyson, B., Pakhomov, S., Karlawish, J., & Shah, R.C. (2019) Paradoxical lucidity: a 
potential paradigm shift for the neurobiology and treatment of severe dementias. Alzheimer’s 
& Deme ntia, 15: 1107 -14. doi:10.1016/j.jalz.2019.04.002.  
Rabinovici, G.D., Seeley, W.W., Kim, E.J., Gorno -Tempi[INVESTIGATOR_9384], M.L.,  Rascovsky, K., Pagliaro, 
T.A., Allison, S.C., Halabi, C., Kramer, J.H., Johnson, J.K., Weiner, M.W., Forman, M.S., 
Trojanowski, J.Q., Dearmon d, S.J., Miller, B.L., & Rosen, H.J. (2007). Distinct MRI atrophy 
patterns in autopsy -proven Alzheimer's disease and frontotemporal lobar  
degeneration.  American journal of Alzheimer's disease and other dementias,  22(6), 474 –488. 
doi: 10.1177/1533317507308779   
Whitwell, J.L., Jack, C.R., Jr,  Przybelski, S.A., Parisi, J.E., Senjem, M.L., Boeve, 
B.F.,  Knopman, D.S., Petersen, R.C., Dickson, D.W., & Josephs, K.A. (2011). 
Temporoparietal atrophy: a marker of AD pathology independent of cli nical diagnosis. 
Neurobiology of aging, 32(9), 1531 –1541. doi : 10.1016/j.neurobiolaging.2009.10.012   
Smith,  S.M.  (2002)  Fast robust automated brain extraction.  Human Brain Mappi[INVESTIGATOR_007],  17:143 -
55.     
Manera A.L., Dadar M.,  Fonov,  V., Collins,  D.L. (2020)  Cereb rA, registration and manual 
label correction of Mindboggle -101 atlas for MNI -ICBM152 template.  Sci Data  7:237.     
Graff -Radford,  J. & Kantarci, K. (2013) Magnetic resonance spectroscopy in Alzheimer’s 
disease.  Neuropsychiatric Disorders & Treatment,  9:687 -96. doi:10.2147/NDT.S35440   
  
Modrego, P.J., & Fayed, N. (2011). Longitudinal Magnetic Resonance Spectroscopy as Marker 
of Cognitive Deterioration in Mild Cognitive Impairment.  American Journal of 
Alzheimer’s  Disease & Other Dementias , 26(8),6310  636.  doi:10.1177/1533317511433809   
  
Mandal, P.K., Saharan, S., Tripathi, M., & Murari, G. (2015b). Brain Glutathione Levels – A 
Novel   Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease.  Biological 
Psychiatry , 78(10), 702 –710. doi:10.1016/j.biopsych. 2015.04.005   
 
Peterson, A.C., & Li, C.S.R. (2018). Noradrenergic Dysfunction in Alzheimer’s and 
Parkinson’s Diseases —An Overview of Imaging Studies.  Frontiers in Aging 
Neuroscience , 10. doi: 10.3389/fnagi.2018.[ADDRESS_755046]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 52  
 
 . . . Hämmerer,  D. (2019). Locus coeruleus imaging as a biomarker for noradrenergic 
dysfunction in neurodegenerative diseases.  Brain , 142(9), 2558  
2571.   doi: 10.1093/brain/awz193   
Olivieri, P., Lagarde, J.,  Lehericy, S.,  Valabrègue, R., Michel, A., Macé, P.,  Caillé, F.,  
Gervais, P.,  Bottlaender, M., & Sarazin, M. (2019). Early alteration of the locus coeruleus in 
phenotypic variants of Alzheimer’s disease.  Annals of Clinical and Translational 
Neurology , 6(7), 1345 –1351.  doi: 10.1002/acn3.[ZIP_CODE]   
Wen, Q., Risacher , L. S., Xie  L., Li, J.,  Harezlak  J., Farlow  R. M., Unverzagt  F. W., 
Gao,  S., Apostolova,  L. G.,  Saykin,  A. J., Wu.  Y., (2021). Tau -related white -matter 
alterations along spatially selective pathways,  NeuroImage,  226 (117560,  1053 -
8119),  https://doi.org/10.1016/j.neuroimage.2020.117560 .   
  
Alexander, A. L., Lee, E., J., Lazar, M., Field, A. S.,  (2007).  Diffusion Tensor Imaging of the 
Brain.  Neurotherapeutics: The Journal of the Am erican Society for 
Experimental  NeuroTherapeutics:  4, 316 -329.  
  
Smith, S. M., Johansen -Berg, H., Jenkinson, M., Rueckert, D., Nichols, T. E., Miller, K. L., 
Robson, M. D., Jones, D. K., Klein, J. C., Bartsch, A. J., & Behrens, T. E. J. (2007). 
Acquisitio n and  voxelwise  analysis of multi -subject diffusion data with Tract -Based Spatial 
Statistics.  Nature Protocols , 2(3), 499 –503. https://doi.org/10.1038/nprot.2007.45   
  
Fu, X., Shrestha S, Sun M, Wu Q, Luo Y, Zhang X, Yin J, Ni H.  (2019).  Microstructural 
White Matter Alterations in Mild Cognitive Impairment and Alzheimer's Disease: Study 
Based on Neurite Orientation Dispersion and Density Imaging (NODDI).  Clin Neuroradiol ; 
30(3):569 -579. doi: 10.1007/s00062 -019-[ZIP_CODE] -0. Epub  2019 Jun 7. PMID: 31175374.   
  
Zarei, M., Patenaude,  B., Damoiseaux,  J., Morgese,  C., Smith, S., Matthews,  P. 
M., Barkhof,  F., Rombouts, S., Sanz -Arigita,  E., Jenkinson, M.  (2010)  Combining shape and 
connectivity analysis: An MRI study of thalamic degeneration in Alzheimer's 
disease,  NeuroImage,  49(1),  1053 -8119,  https://doi.org/10.1016/j.neuroimage.2009.09.001.   
 
Chappell,  M.A.,  Groves,  A.R.,  Whitcher, B.  & Wool rich, M.W. 
(2009)  Variational  bayesian  inference for a  nonlinear  forward  model.  IEEE Transactions on 
Signal Processing , 57(1):223 -6, doi: 10.1109/TSP.2008.2005752.   
Woolrich M.W., Chiarelli P.,  Gallichan  D., Perthen  J., & Liu T.T.  (2006)  Bayesian inference  
of hemodynamic changes in functional arterial spin labeling  
data.  Magn  Reson  Med,  56(4):891 -906. doi: 10.1002/mrm.[ZIP_CODE]. PMID: 16964610.   
Chen,  Y., Wolk,  D.A., Reddin,  J.S., et al.  (2011)  Voxel -level comparison of arterial spin -
labeled perfusion MRI and FDG -PET in Alzheimer disease.  Neurology, 77(22):1977 -
1985.  doi:10.1212/WNL.0b013e31823a0ef7   
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 53  
 
 Ahlgren, A.,  Wirestam, R., Knutsson, L., & Petersen, E. T. (2018). Improved calculation of 
the equilibrium magnetization of arterial blood in arterial spin labe ling. Magnetic resonance 
in medicine, 80(5), 2223 –2231. https://doi.org/10.1002/mrm.[ZIP_CODE]   
Hernandez -Garcia,  L. & Jahanian,  H. & Rowe, D. (2010). Quantitative  analysis 
of arterial  spin labeling  fMRI  data using a  general  linear  model.  Magnetic resonance 
imaging,  28:919 -27. 10.1016/j.mri.2010.03.035.   
Zhang, N., Gordon, M.L., & Goldberg, T.E. (2017). Cerebral blood flow measured by [CONTACT_575166]'s disease.  Neuroscience and 
biobehavioral reviews , 72, 168–175. doi:10.1016/j.neubiorev.2016.11.023   
Wang, L., Zang, Y., He, Y., Liang, M., Zhang, X., Tian, L., Wu, T., Jiang, T., & Li, K. 
(2006). Changes in hippocampal connectivity in the early stages of  Alzheimer’s  disease: 
Evidence from resting  state fmri.  NeuroImage , 31(2), 496 -
504. doi: 10.1016/j.neuroimage.2005.12.033    
  
Sperling, R. (2011). The potential of functional MRI as a biomarker in early Alzheimer’s 
disease.  Neurobiology of Aging , 32 (Suppl 1), S37 –
S43. doi: 10.1016/j.neurobiolaging.2011.09.009   
  
Erhardt, E. B., Rachakonda, S., Bedrick, E. J., Allen, E. A., Adali, T., & Calhoun, V. D. 
(2011). Comparison of multi -subject ICA methods for analysis of fMRI data. Human brain 
mappi[INVESTIGATOR_007], 32(12), 2075 –2095. https://doi.org/10.1002/hbm.[ZIP_CODE]   
  
Salami, A.,  Pudas, S., & Nyberg, L. (2014). Elevated hippocampal resting -state connectivity 
underlies deficient neurocognitive function in aging.  Proceedings of the National Academy of 
Sciences , 111(49), [ZIP_CODE] –[ZIP_CODE].  doi: 10.1073/pnas.[PHONE_11922]   
  
Li, H., Jia, X., Qi, Z., Fan, X., Ma, T., Ni, H., Li, C. R., & Li, K. (2017). Altered Functional 
Connectivity of the Basal Nucleus of  Meynert  in Mild Cognitive Impairment: A Resting -
State fMRI Study.  Frontiers in Aging Neuroscience , 9, 127.  doi: 10.3389/fnagi.2017.0012 7  
  
Miao, X., Wu, X., Li, R., Chen, K., & Yao, L. (2011). Altered connectivity pattern of hubs in 
default -mode network with Alzheimer's disease:  a Granger causality modeling 
approach.  PloS  one, 6(10), e25546.  doi: 10.1371/journal.pone.0025546   
  
O'Brien, J. L., O'Keefe, K. M.,  LaViolette, P. S., DeLuca, A. N., Blacker, D., Dickerson, B. 
C., & Sperling, R. A. (2010). Longitudinal fMRI in elderly reveals loss of hippocampal 
activation with clinical decline.  Neurolog y, 74(24), 1969 –
1976.  doi: 10.1212/WNL.0b013e3181e3966e   
 
Schrag, A., & Schott, J. M. (2011). What is the clinically relevant change on the ADAS -Cog? 
Journal of Neurology, Neurosurgery & Psychiatry, 83(2), 171 –173. doi: 10.1136/jnnp -[ADDRESS_755047]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 54  
 
 Nasreddine,  Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., 
Cummings, J.L., & Chertkow, H. (2005) The montreal cognitive assessment, MoCA: a brief 
screening tool for mild cognitive impairment. Journal of the American Geriatrics Society , 
53(4). doi:10.1111/j.1532 -5415.2005.[ZIP_CODE].  
Berman, S.E., Koscik, R.L., Clark, L.R., Mueller, K.D., Bluder, L., Galvin, J.E., Johnson, 
S.C. (2017) Use of the quick dementia rating system (QDRS) as an initial screening measure 
in a longitudinal cohort at r isk for Alzheimer’s disease. Journal of Alzheimer’s Disease 
Reports, 1(1): 9 -13. doi:10.3222/ADR -17 
Galvin, J.E. (2015) The quick dementia rating system (QDRS): a rapid dementia staging tool. 
(2015) Alzheimers Dement (Amst). 1(2):249 -259. doi:10.1016/j.dad m.2015.03.003.    
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 55  
 
 Appendix 1  Schedule of Events  
Evaluation  Screening Days  
-10 to -1 Clinic Visit  
Day 0  Treatment Period  
Day 1 - 90 Follow -
up (Day s 
91 ± 15)  Day 1  Day 7  Day 15  Day 30  Day 45  Day 60 Day 75  Day 90  
Informed Consent  X           
I/E Criteria  X X          
Demographics  X           
Medical H istory  X           
Physical Examination  X X  X  X  X  X X 
Advanced MRI of the Brain  X          X 
Lumbar Puncture  X          X 
Cognitive Testing  X         X X 
APoE Genotypi[INVESTIGATOR_007]  X           
Vital Signs  X X  X  X  X  X X 
Laboratory Tests  X    X X  X  X X 
Participant ID Assignment  X           
AE Assessment    X X X X X X X X X 
Conmed Assessment  X X X X X X X X X X X 
Discharge From Clinic            X 
 
 
 
NE3107   The Regenesis Project  
Clinical Trial Protocol: NE3107 -TRP-001  Page 56  
 
 Appendix 2  Sponsor Signatures  
Study  Title:  A Phase II, Open -Label Study for the Use of Anti-Inflammatory, 
Insulin -Sensitizing NE3107 for Treatment of Cognitive Decline Due to 
Degenerative Dementia  
Study  Number:  NE3107 -TRP-001 
Final  Date:  Final V1.0 (4 November 2021)  
Amendment 1 Date:   
 
This clinical study protocol was subject to critical  review and has been approved by [CONTACT_142930]. The following personnel contributed to writing and/or approving this protocol:  
 
Signed:    Date:    
Sheldon E. Jordan, MD Inc.  
Principal Investigator  
[INVESTIGATOR_575133]., dba The Regenesis Project  
[ADDRESS_755048]., Suite #790, Santa Monica, CA [ZIP_CODE]  
(310) [ADDRESS_755049]  
Clinical Trial Protocol: NE3107 -TRP-001  Page 57  
 
 Appendix 3  Investigator’s Signature  
[CONTACT_2759]:  A Phase II, Open -Label Study for the Use of Anti -Inflammatory, Insulin -
Sensitizing NE3107 for Treatment of Cognitive Decline Due to 
Degenerative Deme ntia 
Study Number:  NE3107 -TRP-001 
Final Date:  Final V1.0 (4 November 2021)  
Amendment 1 Date:  {revision date}  
The information contained in this protocol and all other information relevant to NE3107 are 
the confidential and proprietary information of Sheldon E. Jordan, MD Inc., dba The 
Regenesis Project, and except as may be required by [CONTACT_1032], state, or local law s or 
regulation, may not be disclosed to others without prior written permission of Sheldon Jordan 
MD Inc.  
 I have read the protocol, including all appendices, and I agree that it contains all of the 
necessary information for me and my staff to conduct th is study as described. I agree to 
comply with all applicable regulations and to conduct the study as described herein, in 
accordance with applicable national, state, and local regulations, and will make a reasonable 
effort to complete the study within the time designated .  
I will provide all study personnel under my supervision copi[INVESTIGATOR_88372], and access to all information provided by [CONTACT_575167], Inc., or 
specified designees. I will discuss the material with them to ensure that they are fully 
informed about NE3107 and the study.  
 
 
Signed:    Date:    
Sheldon E. Jordan, MD  
Principal Investigator  
[INVESTIGATOR_575133]., dba The Regenesis Project  
[ADDRESS_755050]., Suite #790, Santa Monica, CA [ZIP_CODE]  
(310) 829 -5968  